Browse > Article
http://dx.doi.org/10.5351/CKSS.2012.19.6.877

Maximum Tolerated Dose Estimation Applied Biased Coin Design in a Phase I Clinical Trial  

Kim, Yu Rim (Department of Biostatistics, The Catholic University of Korea)
Kim, Dongjae (Department of Biostatistics, The Catholic University of Korea)
Publication Information
Communications for Statistical Applications and Methods / v.19, no.6, 2012 , pp. 877-884 More about this Journal
Abstract
Phase I trials determine the maximum tolerated dose(MTD) and the recommended dose(RD) for subsequent Phase II trials. In this paper, a MTD estimation method applied to a biased coin design is proposed for Phase I Clinical Trials. The suggested MTD estimation method is compared to the SM3 method and the NM method (Lee and Kim, 2012) using a Monte Carlo simulation study.
Keywords
Phase I clinical trial; maximum tolerated dose; recommended dose; biased coin design;
Citations & Related Records
Times Cited By KSCI : 1  (Citation Analysis)
연도 인용수 순위
1 Ahn, C. (1998). An evaluation of phase I cancer clinical trial designs, Statistics in Medicine, 17, 1537- 1549.   DOI
2 Antognini, A. B. and Giovagnoli, A. (2004). A new "biased coin design" for the sequential allocation of two treatments, Italian Statistical Society.
3 Chevret, S. (1993). The continual reassessment method in cancer phase I clinical trials: A simulation study, Statistics in Medicine, 12, 1093-1108.   DOI   ScienceOn
4 Dixon, W. J. and Mood, A. M. (1948). A method for obtaining and analyzing sensitivity data, Journal of the American Statistical Association, 43, 109-126.   DOI   ScienceOn
5 Goodman, S. N., Zhurak, M. L. and Piantadosi, S. (1995). Some practical improvements in the continual reassessment method for Phase I studies, Statistics in Medicine, 14, 1149-1161.   DOI   ScienceOn
6 Kang, S. H. (2002). Investigation on the modified continual reassessment method in phase I clinical trial, Journal of Applied Statistics, 15, 323-336.   DOI   ScienceOn
7 Korn, E. L., Midthune, D., Chen, T. T., Rubinstein, L. V., Christian, M. C. and Simon, R. M. (1994). A comparison of two phase I trial designs, Statistics in Medicine, 13, 1799-1806.   DOI   ScienceOn
8 Lee, N. M. and Kim, D. (2012). Two-stage maximum tolerated dose estimation by stopping rule in a phase I clinical trial, Communications of the Korean Statistical Society.
9 O'Quigley, J. and Chevret, S. (1991). Method for dose finding studies in cancer clinical trials: A review and results of a Monte Carlo study, Statistics in Medicine, 10, 1647-1664.   DOI   ScienceOn
10 O'Quigley, J., Pepe, M. and Fisher, M. (1990). Continual reassessment method: A practical design for phase I clinical trials in cancer, Biometrics, 46, 33-48.   DOI   ScienceOn
11 O'Quigley, J. and Shen, L. Z. (1996). Continual reassessment method: A likelihood approach, Biometrics, 52, 163-174.
12 Park, I. H. (1999). The estimation of maximal tolerated dose in sequential phase I clinical trials, Department of Biostatistics, The Catholic University of Korea, Biostatistics Master's Thesis.
13 Storer, B. E. (1989). Design and analysis of phase I clinical trials, Biometrics, 45, 925-937.   DOI   ScienceOn